Abstract
Cholecystokinin has been found in high concentration in the brain, and has been observed to induce panic attacks in normal volunteers and patients with panic disorder. The purpose of this pilot study is to evaluate the efficacy and safety of L-365,260, a CCKB antagonist in patients with panic disorder. Following a 1 week placebo washout, 10 patients who had a minimum of 4 unexpected panic attacks and rated moderately ill on CGI, were randomized into 6 weeks double-blind treatment phase. Evaluations were done weekly both for safety and efficacy. PGIS was used as primary efficacy parameter. Patients rated ≥ 7 on PGIS were considered responders. Anxiety and depression were measured using the HAM-A and HAM-D scales. Five patients received L-365,260 and 5 received placebo. 60% of the patients on L-365,260 compared to 20% on placebo were improved according to PGIS scores. There was a greater reduction in the number of weekly panic attacks in treatment group thank in the placebo group; mean improvement of anxiety on the HAM-A was seen more on L-365,260 than on placebo. Overall, L-365,260 was well tolerated in the study. Only mild headache was reported. The results at this site tend to favor L-365,260 in patients with panic and anxiety disorder.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shrivastava, R., Shrivastava, S., Overweg, N. et al. Placebo Controlled Double-Blind Trial of L-365,260 CCKB Antagonist in Panic Disorder. Neuropsychopharmacol 11, 285 (1994). https://doi.org/10.1038/sj.npp.1380213
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.npp.1380213